Targeting integrin/CD49D/VLA-4 with natalizumab can inhibitadhesion of malignant B cells and sensitize them tochemoimmunotherapy
2010
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI